Seeking Alpha

MedicNova (MNOV) reports positive results from Phase 1b trials of its pulmonary disease...

MedicNova (MNOV) reports positive results from Phase 1b trials of its pulmonary disease treatment MN-221. The company says the majority of the subjects completed the study and there were no clinically significant safety concerns. In addition, preliminary pharmacokinetic and efficacy findings were encouraging. Shares -2.4% AH.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector